Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21794929 | 1.00 | EPHX2 (0.41) | EPHX2PPARGNTRK1HDAC3HDAC1 | |
| SCHEMBL23572998 | 1.00 | EPHX2 (0.41) | EPHX2PPARGNTRK1HDAC3HDAC1 | |
| SCHEMBL21794930 | 0.89 | NLN (0.43) | — | |
| SCHEMBL21794986 | 0.84 | NLN (0.37) | EPHX2NTRK1PTGES | |
| SCHEMBL21794951 | 0.81 | NLN (0.47) | — | |
| SCHEMBL23572972 | 0.81 | NLN (0.47) | — | |
| SCHEMBL21794974 | 0.81 | NLN (0.47) | — | |
| SCHEMBL23598405 | 0.80 | ALDH1A1 (0.52) | — | |
| SCHEMBL21794935 | 0.80 | ALDH1A1 (0.52) | — | |
| SCHEMBL23572993 | 0.80 | EGFR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-17 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | GAP43, NLN, BDNF | EPHX2 3933/4885PPARG 4365/4885NTRK1 7/4885 |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | GAP43, NLN, BDNF | EPHX2 3933/4885PPARG 4365/4885NTRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.